GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Regenerex Pharma Inc (OTCPK:PEPT) » Definitions » Return-on-Tangible-Equity

Regenerex Pharma (Regenerex Pharma) Return-on-Tangible-Equity : 0.00% (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Regenerex Pharma Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Regenerex Pharma's annualized net income for the quarter that ended in Dec. 2023 was $-1.06 Mil. Regenerex Pharma's average shareholder tangible equity for the quarter that ended in Dec. 2023 was $-3.76 Mil. Therefore, Regenerex Pharma's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 was N/A%.

The historical rank and industry rank for Regenerex Pharma's Return-on-Tangible-Equity or its related term are showing as below:

PEPT's Return-on-Tangible-Equity is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.22
* Ranked among companies with meaningful Return-on-Tangible-Equity only.

Regenerex Pharma Return-on-Tangible-Equity Historical Data

The historical data trend for Regenerex Pharma's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenerex Pharma Return-on-Tangible-Equity Chart

Regenerex Pharma Annual Data
Trend Nov09 Nov10 Nov11 Nov12 Nov13 Nov14 Mar17 Mar18 Mar22 Mar23
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only Negative Tangible Equity - - - -

Regenerex Pharma Quarterly Data
May14 Aug14 Nov14 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Regenerex Pharma's Return-on-Tangible-Equity

For the Medical Instruments & Supplies subindustry, Regenerex Pharma's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regenerex Pharma's Return-on-Tangible-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Regenerex Pharma's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Regenerex Pharma's Return-on-Tangible-Equity falls into.



Regenerex Pharma Return-on-Tangible-Equity Calculation

Regenerex Pharma's annualized Return-on-Tangible-Equity for the fiscal year that ended in Mar. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Mar. 2023 )  (A: Mar. 2022 )(A: Mar. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Mar. 2023 )  (A: Mar. 2022 )(A: Mar. 2023 )
=-0.137/( (-0.993+-1.127 )/ 2 )
=-0.137/-1.06
=N/A %

Regenerex Pharma's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=-1.056/( (-3.636+-3.878)/ 2 )
=-1.056/-3.757
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Regenerex Pharma  (OTCPK:PEPT) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Regenerex Pharma Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Regenerex Pharma's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Regenerex Pharma (Regenerex Pharma) Business Description

Traded in Other Exchanges
N/A
Address
5348 Vegas Drive, Suite 177, Las Vegas, NV, USA, 89108
Regenerex Pharma Inc develops and markets Woundcare Healing products. The current product technology provides the Company with a number of complete wound care protocols to treat all wounds, such as diabetic ulcers, pressure ulcers, burns, and surgical wounds. Its product Xcellderma OTC a Liquid Bandage Skin Protectant Xcellderma products are sterile wound dressings for treating diabetic foot ulcers, pressure ulcers, and other chronic wounds; Accelerex Sterile Wound Cream is for the treatment of a wide variety of chronic and acute wounds; and Accelerex Impregnated Sterile Wound Dressing use as a wound dressing to manage pressure ulcers (stages I-IV), stasis ulcers, diabetic skin ulcers, skin irritations, cuts, and abrasions.

Regenerex Pharma (Regenerex Pharma) Headlines

No Headlines